HOME > BUSINESS
BUSINESS
- FDA Accepts NDA for Ospemifene for VVA: Shionogi
June 29, 2012
- AnGes MG Obtains Exclusive Rights for Vaccine for Precancerous Condition of the Cervix in China
June 28, 2012
- Takeda Ranked No. 1 in Medical Category for 5th Year in a Row: Popularity Rankings for Career Change
June 28, 2012
- DSP Launches Myslee Generic on June 28
June 28, 2012
- Eisai to Make Full-Scale Entry into Russian Market; Antiepileptic Agent Obtains Approval
June 28, 2012
- Yoshindo to Accumulate Know-How to Develop Biopharmaceutical Products through Contract Manufacturing
June 28, 2012
- Astellas Files MAA for Anti-Androgen Agent MDV3100 in Europe
June 28, 2012
- Chugai Applies for Tarceva for NSCLC First-Line Therapy
June 28, 2012
- Takata Seiyaku to Market 3 Products from Shionogi
June 28, 2012
- MSs Want “Client Visits by MRs” for Generic Promotion: Toho Pharmaceutical Survey
June 27, 2012
- Large Number of GEs Could Become Serious Issue: Alfresa Logistics Chief Fukujin
June 27, 2012
- Takeda to Market Iron Deficiency Anemia Drug in Europe
June 27, 2012
- DSP to Ship Almarl under New Brand Name from Mid-July
June 27, 2012
- Azilva Ranks No. 1 Both in GP, HP Market in May: Rep Track Survey
June 27, 2012
- Astellas Launches Kiklin Capsules, Copromotes with SKK
June 26, 2012
- ACE Inhibitors Approved for Pediatric Use: MSD, AZ, Shionogi, Kyowa Pharmaceutical
June 26, 2012
- Amlodipine Besylate Approved for Supplemental Indication of Pediatric Hypertension, Generic Versions also Approved
June 26, 2012
- Pfizer Remains Top, Takeda Ranks 12th in World Ranking in FY2011
June 26, 2012
- EvaluatePharma Forecasts Januvia to Become World’s Best-Selling Product in 2018
June 25, 2012
- RaQualia Receives Substance Patent Evaluation in US for 5-HT2B Antagonist
June 25, 2012
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…